Proceedings book download - 5Z.com

Table 1. Overlapping peptides of tTG(1-230) tested in RIA (underlined residues indicatecommon fragments)Peptide tTG fragment SequenceI tTG(1-25) MAEELVLERCDLELETNGRDHHTADII tTG(16-40) TNGRDHHTADLCREKLVVRRGQPFWIII tTG(31-55) LVVRRGQPFWLTLHFEGRNYEASVDIV tTG(46-60) ENGRYEASVDSLTFSV tTG(56-70) SLTFSVVTGPAPSQEVI tTG(66-80) APSQEAGTKARFPLRVII tTG(76-90) RFPLRDAVEEGDWTAVIII tTG(106-120) TPANAPIGLYRLSLEIX tTG(116-130) RLSLEASTGYQGSSFcpmcpm12000100008000600040002000012000100008000600040005μL wb 5μL(I) 5μL(II) 5μL(III) 5μL(VI) 5μL(VII) 5μL(VIII) 5μL(IX)PEPTIDES (2μg/ μL)CD 2813CD41CD18CD28CD17Peptide fragments reportedin Table 1 were tested inRIA. They showed that tTG(31-55) is able to inhibitanti tTG-Ab binding to theradio-labelled protein (Fig.1) with a dose - responsepattern. Moreover tTG(31-55) induced a remarkabledecrease of the cpmmeasured at the β-counterin all the sera tested. On thebasis of these findings wecan assume that the tTG(31-55) fragment is able toinhibit the tTG-Ab bindingto the radio-labelledprotein.200000 0,4 2 3 4Peptide concentration (μg/μL)Fig. 1. Upper: RIA Screening of the peptides reported inTable1 for a representative patient’serum; Lower: doseresponsecurve of tTG(31-55).AcknowledgmentsThis work is supported by Ente Cassa di Risparmio di Firenze and the ANR Chaire d’ExcellencePepKit 2009-2013 (France).References1. Sollid, LM. Nat Rev. Immunol 2, 647-655 (2002).2. Dieterich, W., et al. Nat. Med. 3, 797-801 (1997).3. Halttunen, T., Mäki, M. Gastroenterology 116, 566-572 (1999).4. Baker, M. Nature Biotech. 23, 297-304 (2005).5. Alcaro, M.C., et al. Chemistry Today 27(2), 36-39 (2009).6. Lolli, F., et al. Expert Rev. Neurotherapeutics 6(5), 781-794 (2006).7. Tiberti, C., et al. Clinical Immunology 121, 40-46 (2006).493